RhumbLine Advisers
HZNP

RhumbLine Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

RhumbLine Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-306,817
Closed -$35.5M – 4332
2023
Q3 		$35.5M Sell
306,817
-4,315
-1% -$464K 0.04% 379
2023
Q2 		$32M Buy
311,132
+37,657
+14% +$3.97M 0.04% 435
2023
Q1 		$29.8M Buy
273,475
+17,073
+7% +$1.89M 0.04% 435
2022
Q4 		$29.2M Buy
256,402
+6,842
+3% +$568K 0.04% 414
2022
Q3 		$15.4M Buy
249,560
+15,000
+6% +$1.05M 0.02% 662
2022
Q2 		$18.7M Buy
234,560
+38,672
+20% +$3.66M 0.03% 574
2022
Q1 		$20.6M Sell
195,888
-2,586
-1% -$252K 0.03% 567
2021
Q4 		$21.4M Buy
198,474
+3,994
+2% +$436K 0.03% 579
2021
Q3 		$21.3M Sell
194,480
-14,439
-7% -$1.5M 0.03% 557
2021
Q2 		$19.6M Sell
208,919
-7,436
-3% -$684K 0.03% 611
2021
Q1 		$19.9M Sell
216,355
-11,746
-5% -$991K 0.03% 581
2020
Q4 		$16.7M Sell
228,101
-1,110
-0.5% -$82.5K 0.02% 633
2020
Q3 		$17.8M Buy
229,211
+2,319
+1% +$160K 0.03% 518
2020
Q2 		$12.6M Buy
226,892
+3,267
+1% +$140K 0.02% 659
2020
Q1 		$6.62M Buy
223,625
+38,670
+21% +$1.31M 0.01% 867
2019
Q4 		$6.7M Buy
184,955
+3,498
+2% +$107K 0.01% 1079
2019
Q3 		$4.94M Sell
181,457
-8,400
-4% -$217K 0.01% 1191
2019
Q2 		$4.57M Sell
189,857
-64,092
-25% -$1.63M 0.01% 1251
2019
Q1 		$6.71M Buy
253,949
+15,164
+6% +$359K 0.01% 1003
2018
Q4 		$4.67M Buy
238,785
+75,099
+46% +$1.47M 0.01% 1146
2018
Q3 		$3.21M Sell
163,686
-21,660
-12% -$412K 0.01% 1391
2018
Q2 		$3.07M Buy
185,346
+3,941
+2% +$60.1K 0.01% 1434
2018
Q1 		$2.58M Sell
181,405
-491
-0.3% -$7.25K 0.01% 1463
2017
Q4 		$2.66M Sell
181,896
-39,957
-18% -$561K 0.01% 1463
2017
Q3 		$2.81M Buy
221,853
+11,010
+5% +$140K 0.01% 1389
2017
Q2 		$2.5M Buy
210,843
+6,871
+3% +$85.5K 0.01% 1441
2017
Q1 		$3.02M Buy
203,972
+7,766
+4% +$126K 0.01% 1314
2016
Q4 		$3.17M Buy
196,206
+9,900
+5% +$180K 0.01% 1176
2016
Q3 		$3.38M Buy
186,306
+9,166
+5% +$179K 0.01% 1103
2016
Q2 		$2.92M Buy
+177,140
New +$2.87M 0.01% 1135
2015
Q3 		– Sell
-9,182
Closed -$319K – 3025
2015
Q2 		$319K Sell
9,182
-60,709
-87% -$1.85M ﹤0.01% 2617
2015
Q1 		$1.81M Buy
69,891
+17,795
+34% +$326K 0.01% 1466
2014
Q4 		$672K Buy
52,096
+784
+2% +$9.81K ﹤0.01% 2070
2014
Q3 		$630K Sell
51,312
-5,380
-9% -$62.5K ﹤0.01% 2069
2014
Q2 		$897K Buy
56,692
+3,762
+7% +$53.7K ﹤0.01% 1901
2014
Q1 		$800K Sell
52,930
-1,570
-3% -$17.7K ﹤0.01% 1941
2013
Q4 		$415K Sell
54,500
-2,400
-4% -$12.9K ﹤0.01% 2368
2013
Q3 		$192K Sell
56,900
-473
-0.8% -$1.25K ﹤0.01% 2802
2013
Q2 		$141K Buy
+57,373
New +$138K ﹤0.01% 3149

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

RhumbLine Advisers's HZNP Position: Q4 2023 in Review

RhumbLine Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 306,817 shares — an estimated $35.5M sold.

RhumbLine Advisers first reported a position in HZNP in Q2 2013 and held it in 39 quarters. The position peaked at $35.5M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • RhumbLine Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • RhumbLine Advisers sold 306,817 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $35.5M.
  • RhumbLine Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 39 quarters.
  • RhumbLine Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $35.5M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on RhumbLine Advisers's 13F filing for Q4 2023, filed 8 Feb 2024.